SEBI Reg. Investment Advisor

Download App
Help Center Subscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Camlin Fine Sciences Ltd (CAMLINFINE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532834 NSE: CAMLINFINE Chemicals | Small Cap | Camlin Fine Sciences Share Price

₹127.25 2.55 (2.04%)

As on 27-Jul'26 16:59

Camlin Fine Sciences Ltd (CAMLINFINE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532834 NSE: CAMLINFINE Chemicals | Small Cap | Camlin Fine Sciences Share Price

₹127.25 2.55 (2.04%)

As on 27-Jul'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹2,395 Cr.
Current Price
₹127.3
52-Week Low / High
₹96 / 281
TTM EPS
₹-1.7
TTM Sales
₹838 Cr.
Book Value per Share
₹47.5
P/E Ratio
0.00
Lower than its 5-year historical median
Industry PE
51.7
Price to Book (P/B)
2.62
Lower than its 5-year historical median
Price to Sales (P/S)
2.86
In line with its 5-year historical median
EV/EBITDA
30.61
In line with its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-3.74%
Underperforms industry median
Return on Capital Employed (ROCE)
1.58%
Underperforms industry median
Return on Assets (ROA)
-2.00%
Operating Profit Margin
6.8%
Net Profit Margin
-3.93%
Gross Profit Margin
1.9%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-5.48%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-29.28%
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
48.03%
Pledged shares (%) of Promoter's holding (%)
16.21%
Reserves
₹894 Cr.
Equity
₹19.2 Cr.
Face Value
₹1
All Time Low / High
₹1.90 / 334.70

Camlin Fine Sciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Not Good
Check detailed performance

Valuation

Fair

Check Valuation charts

Price Trend

Semi Strong
Check Price chart
Q.1 Is Camlin Fine Sciences Ltd a good quality company?
Camlin Fine Sciences Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Camlin Fine Sciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Camlin Fine Sciences Ltd vs industry peers?
Camlin Fine Sciences Ltd revenue CAGR is 6.91%, compared to the industry median CAGR of 7.01%, indicating stable growth and maintaining its market share.
Q.1 Promoter shareholding and pledge status of Camlin Fine Sciences Ltd?
Promoters hold 48.03% of the Camlin Fine Sciences Ltd, with 16.21% of their stake pledged, indicating high pledge risk.
Q.1 Stock return of Camlin Fine Sciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 3.2% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Camlin Fine Sciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ7.4%1.7%6.2%10.6%6.9%7.7%11.3%0.2%-3.9%1.6%-
Value Creation
Index ⓘ		-0.5-0.9-0.6-0.2-0.5-0.5-0.2-1.0-1.3-0.9-

Growth Parameters ⓘ
Sales ⓘ325403548580600686789773886838838
Sales YoY Gr.-24.1%36.1%5.8%3.5%14.2%15.2%-2.1%14.6%-5.5%-
Adj EPS ⓘ0.2-1.30.71.61.11.21.9-3.1-0.7-2-1.7
YoY Gr.--816.7%NA129.6%-32.5%10%59.5%-261.7%NANA-
BVPS (₹) ⓘ16.424.926.230.331.736.13940.945.147.547.5
Adj Net
Profit ⓘ		1.9-16.18.820.214.419.431.1-53.6-13.9-37.5-33
Cash Flow from Ops. ⓘ-30.1-5.2-44.673.92646.818.582.118.144-
Debt/CF from Ops. ⓘ-8.1-41.7-74.514.39.632.6622.710.7-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ11.1%6.9%2%-5.5%
Adj EPS ⓘ-230.3%-212.1%-200.3%NA
BVPSⓘ12.6%8.5%6.8%5.3%
Share Price 3.2% -7.6% -6.1% -52.7%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		1.3-6.32.65.63.43.75-7.9-1.8-4.2-3.6
Op. Profit
Mgn % ⓘ		8.51.1610.412.411.616.84.38.96.85.7
Net Profit
Mgn % ⓘ		0.6-41.63.52.42.83.9-6.9-1.6-4.5-3.9
Debt to
Equity ⓘ		1.40.710.90.90.810.70.50.50.2
Working Cap
Days ⓘ		322338305315338344366415348366195
Cash Conv.
Cycle ⓘ		18118015216216816519323316316069

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales325403548580600686789773886838
Operating Expenses ⓘ + 301399515519534606657741807782
Manufacturing Costs293442506496157169184188
Material Costs204303409389378395366444481446
Employee Cost 22212328395360667276
Other Costs ⓘ 47414252546375627072
Operating Profit ⓘ 23433606679132337956
Operating Profit Margin (%) 7.2%1.0%6.0%10.4%10.9%11.6%16.8%4.2%8.9%6.7%
Other Income ⓘ + 1413142782029212135
Exceptional Items ⓘ 000-3-100-2-96-16
Interest ⓘ 26262331383662627575
Depreciation ⓘ 129911192733495354
Profit Before Tax ⓘ 0-181441153667-60-123-54
Tax ⓘ 1-431171019-8-47-21
Profit After Tax -1-14113182648-51-76-33
PAT Margin (%) -0.2%-3.5%2.0%5.3%1.4%3.8%6.0%-6.7%-8.6%-3.9%
Adjusted EPS (₹)-0.1-1.10.92.50.61.63.0-3.0-4.1-1.7
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Valuation of Camlin Fine Sciences - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 174309325376413580628702848913
Share Capital ⓘ 10121212131616171919
Reserves ⓘ 164297313364400564612685829894
Debt +234215310331363438512456364400
Long Term Debt1114111113163258292222172210
Short Term Debt223200199218201180220233192190
Minority Interest0000000000
Trade Payables36114106133193212249284297316
Others Liabilities ⓘ 29383951971162051307777
Total Liabilities ⓘ 4746767808911,0671,3461,5941,5721,5861,706

Fixed Assets

Net Fixed Assets ⓘ +76708094292304583577567526
Gross Block8890109131348381682723765775
Accumulated Depreciation11202937567799147198249
CWIP ⓘ 142068198182072831923
Investments ⓘ 44148697474828280102217
Inventories11611510997131142252255263244
Trade Receivables131211262323368441526492414474
Cash Equivalents 13116913825610148581
Others Assets ⓘ 7810112292102113113123147142
Total Assets ⓘ 4746767808911,0671,3461,5941,5721,5861,706

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + -30-5-4574264719821844
PBT ⓘ 0-181441153667-60-123-54
Adjustment ⓘ 29191922655576144177110
Changes in Working Capital ⓘ -52-6-7412-44-43-11716-34-12
Tax Paid ⓘ -7-0-4-1-10-1-7-18-1-0
Cash Flow From Investing Activity ⓘ + -31-116-3-66-88-172-115-52-88-30
Capex -6-15-52-115-39-189-131-41-22-27
Net Investments -26-1024344-502829-8-652
Others ⓘ 21552-11-12-3-1-6
Cash Flow From Financing Activity ⓘ + 6112065-268012978-34105-13
Net Proceeds from Shares ⓘ 581480001112231
Net Proceeds from Borrowing ⓘ -14-2-10-2468891-1-4836
Interest Paid ⓘ -23-24-31-39-40-31-39-47-54-40
Dividend Paid ⓘ -5000000000
Others ⓘ 45-21061674712613-17-10
Net Cash Flow ⓘ 0-117-18183-18-4350

Financial Ratio

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)-0.54-5.873.388.762.15.217.87-7.73-9.85-3.74
ROCE (%)7.361.656.1910.596.97.7211.280.18-3.891.58
Asset Turnover Ratio0.790.70.750.690.610.570.540.490.560.51
PAT to CFO Conversion(x)N/AN/A-4.092.393.251.810.4N/AN/AN/A
Working Capital Days
Receivable Days124.20154.50157.60184.30210.40215.30223.50240.30186.60193.50
Inventory Days126.80104.2074.606569.5072.9091.20119.60106.70110.40
Payable Days10490.6098.30112.10157.20187.10229.80219.30220.50250.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *12.4312.4312.4312.4310.840.0010.8410.8416.5816.21
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Camlin Fine Sciences Ltd FAQs

The current trading price of Camlin Fine Sciences on 27-Jul-2026 16:59 is ₹127.2.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 26-Jul-2026 the market cap of Camlin Fine Sciences stood at ₹2,395.4 Cr

The latest P/E ratio of Camlin Fine Sciences as of 26-Jul-2026 is 0.00.

The latest P/B ratio of Camlin Fine Sciences as of 26-Jul-2026 is 2.62.

The 52-week high of Camlin Fine Sciences is ₹281.0 and the 52-week low is ₹96.30.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Camlin Fine Sciences is ₹838 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Camlin Fine Sciences Ltd is a below average quality company.

The key valuation ratios of Camlin Fine Sciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Camlin Fine Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Camlin Fine Sciences Ltd

Camlin, the corporate group, was established in 1931 and is a pioneer in art and stationery material in India. Camlin diversified into Pharmaceuticals and Fine Chemicals two decades ago. The Fine Chemical Division of Camlin got de-merged into a separate company named as Camlin Fine Chemicals on 22nd December 2006. The entire management team and employees of Camlin Fine Chemicals Division are now a part of the independent legal entity formed under the Indian Companies Act 1956. In 2011
Company changed its name from Camlin Fine Chemicals Ltd. to Camlin Fine Sciences Ltd. 

Camlin Fine Chemicals is the world's second largest manufacturer and marketer of food grade antioxidants TBHQ and BHA. Its mission is to be the largest food antioxidant and ingredient manufacturer worldwide. Their facilities are HACCP and ISO 9001 : 2000 certified.

Product Range:

a) Food Ingredients –

Antox TBHQ (HACCP Certified) FCC V / FAO / WHO (Tertiary Butyl Hydroquinone)

Antox BHA (HACCP Certified) FCC V / FAO / WHO / EEC ( Butyl Hydroxy Anisole)

b) Sweetener -

Sucralose FCC V

c) Active Pharmaceutical Ingredients -

  • Miconazole Nitrate B.P. / USP
  • Clotrimazole B.P. / USP
  • Amlodipine Besilate E.P
  • Amlodipine Salts
  • Advance intermediate of Amlodipine
  • Intermediate of Miconazole Nitrate

d) Super Absorbent Polymer

Subsidiary Details:

  • Chemolutions Chemicals: Specialty Chemical Intermediates
  • Sangam Laboratories: Nutraceuticals
  • Fine Renewable Energy.
  • Fine LifeStyle Brands: Luxury Fashion Brands

On 6th June 2008 - The company entered into a joint venture, on 51:49 basis, with US based Viachem LLC, to set up a joint venture company under the name Dulcette Technologies for marketing Sucralose, Aspartame, and Acesulfame-K, and their belnds in USA, Canada, and Maxico.

On 7th July 2008 - The Board of Directors of the company at its meeting held on 29th July 2008, approved the proposal for setting up a joint venture company with Pagoda Advisors and their associates.

As per the deal, Camlin Fine Chemicals will get 51% of the equity of the proposed new company and the rest 49% will be owned by Pagoda Advisors and their associates.The proposed new company will focus on the retail of luxury/premium brands in India by setting up stores in all stores in all major metros and cities in India by itself and through franchisees.

On 25th February 2008:  Camlin Fine Chemicals acquired 60% equity stake in Sangam Laboratories, a Small Scale Unit manufacturing Nutraceuticals and Drug Intermediates at Tarapur.

On 12th February 2008 - The company inked a joint venture deal with US based Advanced Aerospace Technologies to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets.

You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: